Our work started with the aim to identify how medically approved medicines influence the expression of PD‐L1, as PD‐L1 levels were previously shown to be potential biomarkers of efficacy of cancer immunotherapies using antibodies against PD‐1 or PD‐L1 [24]. Here, CD274 is linked to cancer.